NurExone Biologic Inc. closes private placement financing

On January 5, 2024, NurExone Biologic Inc. (formerly, EnerSpar Corp.) ("NurExone") (TSXV: NRX) announced that it closed a private placement financing through the issuance of 7,091,993 units of the company for gross proceeds of $1,985,758.04.

NurExone is a pharmaceutical company that is developing a platform for biologically-guided ExoTherapy to be delivered, non-invasively, to patients who suffered traumatic spinal cord injuries. ExoTherapy was conceptually demonstrated in animal studies at the Technion, Israel Institute of Technology. NurExone is translating the treatment to humans, and holds an exclusive worldwide license from the Technion and Tel Aviv University for the development and commercialization of the technology.

Gowling WLG advised NurExone with respect to this private placement with a team that included Jason A. Saltzman, Andrew Avis and student-at-law Derek Varrin.